[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:children":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,100,0,25,[9,44,74,108,136,169,198,228,254,275,306,328,359,389,413,444,471,498,521,546,565,587,611,647,678],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100474390","phase-3-a-study-to-learn-more-about-how-safe-the-study-treatment-finerenone-is-in-long-term-use-when-taken-with-an-ace-inhibitor-or-angiotensin-receptor-blocker-over-18-months-of-use-in-children-and-young-adults-from-1-to-18-years-of-age-with-chronic-kidney-disease-and-proteinuria-100474390",false,"NCT05457283","A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria","An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria","FIONA OLE","Inclusion Criteria:\n\n* Participants must be ≥1 year to 18 years of age, at the time of signing the informed consent\u002Fassent.\n* Prior participation in the finerenone Phase 3 study FIONA (19920) and not permanently discontinued from treatment by the end of treatment (EoT) visit in FIONA.\n* Participants must have a clinical diagnosis of chronic kidney disease (CKD) at Visit 1 which is defined as\n\n  * CKD stages 1-3 (estimated glomerular filtration rate \\[eGFR\\] ≥30 mL\u002Fmin\u002F1.73m\\^2) for children ≥1 year to \\\u003C19 years of age at FIONA EoT and at Visit 1\n* Treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at optimized doses defined as maximally tolerable doses within the recommended dose range according to guidelines on blood pressure (BP) management, unchanged for at least 30 days prior to Visit 1.\n* K+ ≤5.0 mmol\u002FL for children ≥2 years of age at both FIONA EoT and Visit 1, and ≤5.3 mmol\u002FL for children \\\u003C2 years of age at both FIONA EoT and Visit 1\n* Participants who have reached legal age of consent: Capable of giving signed informed consent.\n* Participant is able to receive enteral feeding (solid food, bottle or cup fed, feeding through nasogastric or gastric feeding tubes) with or without breastfeeding.\n\nExclusion Criteria:\n\n* Planned urological surgery expected to influence renal function\n* Patients who are candidates for renal transplantation, i.e., a kidney transplantation scheduled within the study time frame\n* Systemic hypertension Stage 2 defined according to institutional guidelines on BP management at Visit 1.\n* Systemic hypotension defined as symptomatic hypotension or a mean systolic BP below the 5th percentile for age, sex and height but no lower than 80 mmHg for participants \\\u003C18 years and symptomatic hypotension or a mean systolic blood pressure (SBP) \\\u003C90 mmHg in participants ≥18 years at Visit 1.\n* Known hypersensitivity to the study treatment (active substance or excipients)\n* Severe hepatic insufficiency defined by e.g. Child-Pugh C or analogous scores.\n* Participants using rituximab, cyclophosphamide, abatacept, or intravenous glucocorticoids\n* Concomitant therapy with a mineralocorticoid receptor antagonist (MRA)(eplerenone, spironolactone, esaxerenone, canrenone), any renin inhibitor (aliskiren, enalkiren, remikiren), any sodium-glucose co-transporter-2 (SGLT2) inhibitor (SGLT2i), sacubitril\u002Fvalsartan combination (ARNI), or potassium-sparing diuretic (amiloride, triamterene)\n* Concomitant therapy with both ACEI and ARBs together\n* Concomitant therapy with strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, moderate or strong CYP3A4 inducers\n* Previous assignment to treatment during this study\n* Simultaneous participation in another interventional clinical study (e.g., Phase 1 to 4 clinical studies).\n* Any suspected (serious) adverse event related to study intervention which led to permanent discontinuation during the FIONA study.\n* Pregnant or breastfeeding or intention to become pregnant during the study","ALL","1 Year","18 Years",{"count":5,"type":22},"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.\n\nThe kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and\u002For proteinuria. These include \"angiotensin-converting enzyme inhibitors\" (ACEI) and \"angiotensin receptor blockers\" (ARB). Both ACEI and ARB can help improve kidney function by reducing the activity of the renin-angiotensin-aldosterone system (RAAS). The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can impair the ability of the kidneys to work properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system.\n\nThe study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB.\n\nSo, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function.\n\nThe main purpose of this study is to learn how safe the treatment is when used of finerenone in addition to an ACEI or ARB in long-term.\n\nTo see how safe the treatment is, the study team will collect information on medical problems which are also known as \"treatment emergent adverse events\" (TEAEs). And they will also collect levels of an electrolyte called potassium in the blood by taking blood samples, and measure blood pressure during the study.\n\nThe secondary purpose of this study is to learn how well long-term use of finerenone can reduce the amount of protein in the participants' urine and benefit kidney function when taken with standard of care.\n\nTo see how the treatment works, the study team will collect participants' urine samples to assess urinary albumin-to-creatinine ratio (UACR) and urinary protein-to-creatinine ratio (UPCR), which are important assessments for calculating the level of protein in the urine. Researchers will also collect blood samples to analyze serum creatinine and calculate estimated glomerular filtration rate (eGFR). A significant decline in eGFR indicates worsening kidney function.\n\nThe study will include participants who had previously participated in FIONA study (NCT05196035). The participants will be aged from 1 year up to 18 years.\n\nThe participants will be in the study for approximately 19 months. They will take study treatment for up to 18 months and will be follow up for 1 month. During this period, at least 12 visits are planned for patients who newly start finerenone, and at least 8 visits for patients who already received finerenone.\n\nIn the visit, the study team will:\n\n* have their blood pressure, heart rate, temperature, height and weight measured\n* have blood and urine samples taken\n* have physical examinations\n* have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart)\n* answer questions about their medication and whether they have any adverse events, or have their parents or guardian's answer\n* answer questions about how they are feeling, or have their parents or guardian's answer\n* answer question about how they like the study medication, or have their parents or guardian's answer The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.\n\nThe doctors will check the participants' health about 30 days after the participants take their last treatment.",[28,29,30],"Chronic Kidney Disease","Proteinuria","Children","RECRUITING","2026-08-19",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":37,"type":35},"2022-11-08",{"date":39,"type":22},"2028-11-07",{"name":41,"class":42},"Bayer","INDUSTRY",133,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":4,"leadSponsor":70,"locationsCount":73},"100196174","cerebral-palsy-and-the-study-of-brain-activity-during-motor-tasks-100196174","NCT01829724","Cerebral Palsy and the Study of Brain Activity During Motor Tasks","Near-infrared Spectroscopy and Electroencephalography to Assess and Train Cortical Activation During Motor Tasks","* INCLUSION CRITERIA\n* Age 5 years and older\n* Surgery free for six months in either the upper or lower extremities.\n* Free from botulinum toxin injections within four months in either the upper or lower extremities.\n* Either a healthy volunteer or have a diagnosis of a childhood-onset (before 13 years of age) brain injury resulting in motor impairment of one arm and one leg on the same side of the body or motor impairment of both legs or have a diagnosis of childhood-onset (before 13 years of age) peripheral injury resulting in sensory or motor impairment of any limb or multiple limbs.\n* Able to understand and follow simple directions that include how to perform a repetitive task and when to start and stop doing the task, based on parent report if the subject is a child and physician observation during history and physical examination.\n* Able to walk at least 20 feet without stopping with or without a walking aid\n* Able to provide informed consent (Guardian or parent of child participants) or verbal\u002Fwritten assent as appropriate (for child participant).\n* Agreement to not drink caffeine or alcohol for 24 hours before each assessment session because both agents can modify brain activity and may confound outcome measures. This restriction does not apply to the training sessions in Objective 3.\n\nEXCLUSION CRITERIA:\n\n* Any neurological, musculoskeletal or cardiorespiratory injury, health condition, or diagnosis other than childhood-onset brain or peripheral injury that would affect the ability to mentally concentrate or move a body part repetitively for short periods of time. Examples of this include, but are not limited to, congestive heart failure, end stage cardiac disease, or fractures that have not completely healed.\n* Uncontrolled seizures.\n* Concurrent use of medicines for muscle tone (e.g., baclofen, trihexyphenedyl, dantrolene sodium, tizanidine, or carbidopa\u002Flevodopa). If patients are taking these medications daily, the treating physician will be contacted by the MAI to determine if it is acceptable for the subject to temporarily discontinue the medication(s) for 24 hours prior to participating in testing for this study for each of the first 2 objectives. If that is not deemed to be safe, the subject will be excluded. Subjects who are on these medications will not be allowed to participate in Objective 3.\n* Pregnancy: Childbearing potential will be determined during the history and physical exam and urine pregnancy test may be required\n* Adult who can t consent for themselves.\n\nTo participate in Objective 1, it is preferable that all subjects be willing and able to have, or have previously had, a structural MRI to aid in the interpretation of results. Inability or refusal to complete an MRI, or to provide access to a previous structural MRI scan, will not constitute an exclusion criterion for this study.\n\nAdditional exclusion criteria for MRI\n\n* Inability to lie flat on the back for up to 45 minutes without sedation.\n* Discomfort being in small spaces for up to 45 minutes.\n* Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth that cannot be safely removed.\n\nAdditional exclusion criteria for EEG\n\n-History of allergic reaction to water-based electrode gel",true,"5 Years","100 Years",{"count":55,"type":22},320,"OBSERVATIONAL","Background:\n\n\\- Two ways to study the brain while people are moving are near-infrared spectroscopy (NIRS) and electroencephalography (EEG). NIRS uses light to look at blood flow in the brain when it is active. EEG records electrical activity in the brain. Both have been used safely for many years, even in very young children. NIRS or EEG can be used while a person is moving to show which parts of the brain are the most active. Researchers want to use NIRS and EEG to study brain activity during movement in people with cerebral palsy and healthy volunteers. Learning more about how people with and without cerebral palsy use their brain to control their muscles may lead to new ways of training people with cerebral palsy to move better.\n\nObjectives:\n\n\\- To study how the brain controls body movement in people with and without cerebral palsy.\n\nEligibility:\n\n* Individuals at least 5 years of age who have cerebral palsy.\n* Healthy volunteers at least 5 years of age.\n\nDesign:\n\n* This study has three parts. People with cerebral palsy will be selected for all three. Healthy volunteers will be asked to do only two of them. Everyone who participates will have NIRS and\u002For EEG exams during movement. People with cerebral palsy may also have biofeedback sessions to train coordination of movement and brain activity.\n* Participants will be screened with a physical exam and medical history. Urine samples may be collected.\n* All participants will have at least one session of NIRS and\u002For EEG imaging studies. Sessions may also include the following tests:\n* Magnetic resonance imaging to look at the brain\n* Electromyography to measure electrical activity of the muscles\n* Motion analysis of specific body parts\n* Ultrasound to measure activity of the muscles\n* Motorized, robotic, and electrical stimulation of the muscles\n* Other clinical tests of muscle movement as needed.\n* Participants with cerebral palsy will have biofeedback sessions. These sessions will help them learn to coordinate muscle movement and brain activity.",[59,30],"Cerebral Palsy",[61,59,62,63,64],"Functional Brain Imaging","Motion Analysis","Macro-EMG","Natural History","2026-08-15",{"date":67,"type":35},"2026-08-18",{"date":69,"type":35},"2013-08-22",{"name":71,"class":72},"National Institutes of Health Clinical Center (CC)","NIH",1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":73},"100650684","phase-4-comparing-esketamine-and-remazolam-with-propofol-for-breathing-safety-in-pediatric-gastroscopy-100650684","NCT07748884","Comparing Esketamine and Remazolam With Propofol for Breathing Safety in Pediatric Gastroscopy","A Comparative Study on the Incidence of Respiratory Adverse Events Between Esketamine Combined With Remazolam and Traditional Propofol in Pediatric Gastroscopy","Inclusion Criteria:\n\n1. Age 6 to 12 years, both sexes;\n2. American Society of Anesthesiologists (ASA) physical status I or II;\n3. Scheduled for elective gastroscopy or esophagogastroduodenoscopy (EGD) under anesthesia;\n4. Preoperative oxygen saturation of 100% while breathing room air;\n5. Weight within the normal range for age and gender according to the following reference values (inclusive of endpoints)\n\nExclusion Criteria:\n\n1. Contraindications to sedation or anesthesia, or a history of adverse events related to sedation\u002Fanesthesia；\n2. Known or suspected allergy to the study drug, benzodiazepines, or their reversal agents；\n3. History of respiratory disease within the past 2 weeks, or known difficult airway (modified Mallampati score III or IV)；\n4. History of cardiac, hepatic, renal dysfunction, or metabolic diseases；\n5. Patients with congenital diseases or other conditions that may interfere with the evaluation of efficacy outcomes.","6 Years","12 Years",{"count":84,"type":22},120,[86],"PHASE4","Gastroscopy is important for diagnosing and treating upper gastrointestinal diseases in children. To ensure the procedure is safe and smooth, most children require sedation. Compared to adults, children have more fragile airways, lower lung capacity, and poorer oxygen reserves, making them more prone to breathing difficulties and low oxygen levels during sedation.\n\nEsketamine, a stronger form of ketamine, helps maintain heart rate and blood pressure and may reduce breathing-related risks. Remimazolam, a new short-acting sedative, acts quickly, allows faster recovery, and has a better safety profile than propofol-it doesn't cause breathing problems or injection pain.\n\nThe safety and effectiveness of combining remimazolam with esketamine for pediatric gastroscopy have not been well studied. This research will compare this new combination with the traditional propofol-based approach to evaluate its potential benefits and safety in children.",[89,90,30,91,92,93],"Adverse Respiratory Events","Hypoxemia","Gastroscopy","Esketamine","Remimazolam",[95,90,30,96,92,93],"Adverse respiratory events","gastroscopy","NOT_YET_RECRUITING","2026-08-04",{"date":100,"type":35},"2026-08-06",{"date":102,"type":22},"2026-08",{"date":104,"type":22},"2026-12",{"name":106,"class":107},"Second Affiliated Hospital of Wenzhou Medical University","OTHER",{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":73},"100646040","testing-and-evaluation-of-the-returning-to-the-land-intervention-to-address-and-prevent-substance-misuse-100646040","NCT07695818","Testing and Evaluation of the Returning to the Land Intervention to Address and Prevent Substance Misuse","Inclusion Criteria:\n\n* Reside on or near the Rocky Boy Reservation (\\~50-mile round trip);\n* Aged 14-19 years;\n* Parent or primary caregiver to at least one child who will be age 1-5 years at the start of the intervention.\n\nExclusion Criteria:\n\n* Any condition preventing meaningful participation (e.g., lacking capacity to consent or planned relocation precluding attendance).","14 Years","19 Years",{"count":117,"type":22},60,[119],"NA","This study aims to test the Returning to the Land intervention in partnership with a tribal community. The program is designed to address caregiver substance use and child emotional and behavioral development.",[122,30,123],"Substance Use","Cultural Factors",[125,126,127],"substance use","Cultural practices","Effects on youth",{"date":129,"type":35},"2026-08-05",{"date":131,"type":35},"2026-06-15",{"date":133,"type":22},"2029-04",{"name":135,"class":107},"Johns Hopkins Bloomberg School of Public Health",{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":51,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100633670","evaluation-of-a-multicomponent-early-intervention-for-childhood-obesity-prevention-in-vulnerable-families-100633670","NCT07529704","Evaluation of a Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable Families","Evaluation of a Tailored Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable Families (Bambú Project): Randomized Controlled Trial With a Hybrid Type 1 Effectiveness-implementation Design","Bambú","Inclusion Criteria:\n\n* Mothers and\u002For fathers aged 18 years or older.\n* Primary caregivers of a healthy child aged 6 months to 3 years, born at term (≥37 weeks of gestation).\n* At least one parent with overweight or obesity (as defined by BMI criteria).\n* Families in a situation of vulnerability, defined as meeting ≥1 of the following criteria: (1) Low educational level of at least one parent (≤ lower secondary education or equivalent); (2) Precarious employment situation during the past year, (3) Perceived financial difficulties during the past year; (4) Insecure or unstable housing conditions; (5) Single-parent family or prolonged absence of one of the primary caregivers; (6) Recent immigration (≤10 years) without a stable support network or with language barriers.\n\nExclusion Criteria:\n\n* Parents of a child aged 6 months to 3 years with low birth weight (\\\u003C2500 g)\n* Parents of a child aged 6 months to 3 years from a multiple birth (e.g., twins, triplets)\n* Parents\u002Fcaregivers of a child aged 6 months to 3 years with congenital conditions, chronic diseases, or severe disabilities that may affect feeding, growth, or participation in the study\n* Parents or caregivers with severe physical or mental health conditions that would limit their ability to participate in the intervention or assessments\n* Families planning to move out of the study area during the study period",{"count":145,"type":22},526,[119],"Childhood obesity is a public health concern. Evidence-based, multicomponent, parenting interventions targeting early childhood and adapted to families' socioeconomic context are needed to prevent childhood obesity.\n\nThis study aims to evaluate the effectiveness of an early intervention in primary care for the prevention of childhood obesity, targeting vulnerable families where the mother and\u002For the father has overweight or obesity.\n\nMore specifically, the primary aim of this study is to evaluate the effectiveness the intervention to maintain a healthy weight in children aged 6 months to 3 years, measured by the BMI-for-age z-score at baseline, 6, 12, and 18 months, compared to usual care.\n\nThe study also aims to evaluate the effectiveness of the intervention, compared to usual care, for: promoting responsive feeding, improving dietary intake, improving parents' and children's physical activity levels, improving parents' eating styles, and improving children's sleep.\n\nFinally, the study aims to determine the feasibility of implementing the intervention, and to identify factors influencing change and contextual factors in the implementation process.\n\nA pragmatic cluster randomized controlled trial will be conducted. Approximately 526 families (parent-child family dyads) will be recruited, belonging to approximately 76 primary care centers. Primary care centers will be randomly assigned to either an intervention or control group.\n\nThe intervention has been previously co-designed with families and healthcare professionals, and consists of five weekly sessions and four monthly sessions, lasting two hours each. It will be delivered by previously trained healthcare professionals or by members of the research team, depending on the preferences and availability of the primary care center professionals. Approximately 38 intervention face-to-face groups will be conducted, one in each primary care center allocated to the intervention group.\n\nThe study will be conducted in Catalonia, Andalusia, the Balearic Islands and Castile and León (Spain).\n\nEffectiveness outcomes include child body mass index (BMI) z-score, parent feeding practices (measured with the Feeding Practices and Structure Questionnaire), child dietary intake (measured with the multiple-pass 24-hour recall), parents' eating behaviours (measured with the Dutch Eating Behavior Questionnaire), child movement (measured with the Movement Behavior Questionnaire), parents' movement behaviours (measured with the Brief Physical Activity Assessment Tool), and child sleep (measured with selected items from the Brief Infant Sleep Questionnaire).\n\nImplementation and feasibility outcomes will be assessed through interviews during and at the end of the intervention, and through attendance sheets and a final satisfaction questionnaire.\n\nThis study will provide pioneering insights into the implementation and effectiveness of this intervention within the public healthcare system in Spain. This will allow the potential implementation in the future at a larger scale.",[149,150,30,151],"Obesity & Overweight","Vulnerable Families","Families With Infants",[153,154,155,156,157,158,159],"Pediatric obesity","Prevention","Vulnerable populations","Randomized controlled trial","Primary health care","Early intervention","Parenting interventions","2026-08-03",{"date":129,"type":35},{"date":163,"type":35},"2026-03-02",{"date":165,"type":22},"2028-09",{"name":167,"class":107},"Helena Vall Roqué",4,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":186,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":194,"leadSponsor":196,"locationsCount":73},"100650603","effect-of-vibration-and-shotblocker-on-pain-and-fear-levels-during-intramuscular-injection-in-children-in-the-emergency-department-100650603","NCT07750626","Effect of Vibration and ShotBlocker on Pain and Fear Levels During Intramuscular Injection in Children in the Emergency Department","The Effect of Vibration and ShotBlocker on Pain and Fear Levels During Intramuscular Injection in Children in the Emergency Department: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Volunteering of the child and parent to participate in the study,\n* Children the ages between 5-10,\n* Having intramuscular (IM) injection.\n\nExclusion Criteria:\n\n* Communication problem,\n* Children with any chronic illness,\n* Taking any medication that has an analgesic effect at least 6 hours before applying.","10 Years",{"count":84,"type":22},[119],"This prospective study is planned as a randomized controlled study. The aim of this study is to investigate the effects of vibration and the ShotBlocker method on pain and fear levels in children during intramuscular injection in the emergency department.",[30,181,182,183,184,185],"Pain Management","Vibration","Shotblocker","Intramuscular Injection","Intramuscular Injection Pain",[30,187,182,188,184,189,190],"Pain","ShotBlocker","Fear","Emergency Department","2026-08-02",{"date":100,"type":35},{"date":191,"type":35},{"date":195,"type":22},"2026-11-16",{"name":197,"class":107},"Burdur Mehmet Akif Ersoy University",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":20,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":73},"100644494","phase-4-vitamin-d2-vs-vitamin-d2-plus-calcitriol-in-cholestatic-children-with-vitamin-d-deficiency-100644494","NCT07670611","Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D Deficiency","Accelerated Correction of Vitamin D Deficiency in Cholestatic Children: a Comparative Trial of Vitamin D2 Monotherapy vs Combination Therapy With Calcitriol","VITD-CHOL","Inclusion Criteria:\n\n* Patients younger than 18 years of age.\n* Patients diagnosed with cholestasis, defined as direct\u002Fconjugated bilirubin \\>1 mg\u002FdL for more than 1 month.\n* Patients diagnosed with chronic liver disease.\n* Patients with vitamin D deficiency, defined as serum 25-hydroxyvitamin D (25-OHD) level \\\u003C20 ng\u002FmL, according to the Endocrine Society Clinical Practice Guideline.\n\nExclusion Criteria:\n\n* Pre-existing hypercalciuria, screened by urine calcium testing before enrollment.\n* Patients with benign or malignant tumors.\n* Patients with renal tubular defects, screened by electrolyte testing before enrollment.\n* Patients currently receiving anticonvulsant therapy.\n* Patients who do not attend scheduled follow-up visits.",{"count":207,"type":22},54,[86],"The goal of this clinical trial is to learn whether adding calcitriol to vitamin D2 can improve vitamin D deficiency in children with cholestasis and chronic liver disease. Cholestasis is a condition in which bile flow is reduced, which can make it difficult for the body to absorb and process vitamin D. The study will also learn about the safety of using vitamin D2 together with calcitriol.\n\nThe main questions it aims to answer are:\n\n* Does vitamin D2 plus calcitriol increase blood 25-hydroxyvitamin D (25-OHD) levels more than vitamin D2 alone after 3 months of treatment?\n* Does vitamin D2 plus calcitriol help more children reach an adequate vitamin D level by 3 and 6 months?\n* What medical problems, especially high calcium or high phosphorus levels, occur during treatment?\n\nResearchers will compare children who receive vitamin D2 alone with children who receive vitamin D2 plus calcitriol to see which treatment improves vitamin D levels more effectively and safely.\n\nParticipants will:\n\n* Take vitamin D2 alone or vitamin D2 plus calcitriol as assigned by randomization\n* Visit the clinic for study assessments at the start of the study, at 3 months, and at 6 months\n* Have blood tests to measure vitamin D levels, calcium, phosphorus, parathyroid hormone, liver function, and other safety markers\n* Have their treatment reviewed at 3 months; participants whose vitamin D level remains low may have their treatment adjusted according to the study plan\n* Bring back medication packages so researchers can check how regularly the study medicines were taken",[211,212,213,30],"Cholestatic Liver Disease","Chronic Liver Disease (CLD)","Vitamin D Deficiency",[215,216,217,218,219],"cholestasis","pediatrics","vitamin d deficiency","Calcitriol","25-Hydroxyvitamin D2","2026-07-31",{"date":160,"type":35},{"date":223,"type":35},"2026-04-28",{"date":225,"type":22},"2027-04-20",{"name":227,"class":107},"Chulalongkorn University",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":51,"sex":18,"minAge":52,"maxAge":82,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":242,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":73},"100649503","effective-implementation-control-trial-100649503","NCT07736443","Effective Implementation Control Trial","A Theory-Driven Digital Family Engagement Intervention to Improve Children's Oral Health: A Hybrid Effectiveness-Implementation Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n1. Parent or primary caregiver of a child enrolled in a participating primary school.\n2. Child aged 5-12 years (or the age range specified by the study).\n3. Parent or caregiver owns or has regular access to a smartphone with an active WhatsApp account.\n4. Parent or caregiver is able to read and understand the study language(s) (e.g., Urdu and\u002For English).\n5. Parent or caregiver is willing to receive WhatsApp messages throughout the intervention period.\n6. Parent or caregiver provides written informed consent; child provides assent where age-appropriate.\n\nExclusion Criteria:\n\n1. Parent or caregiver declines or withdraws informed consent.\n2. Child has a medical, developmental, or cognitive condition that would prevent participation in routine oral health assessments or toothbrushing activities, as determined by the investigators.\n3. Child is currently participating in another oral health intervention or clinical trial that could influence the study outcomes.\n4. Parent or caregiver plans to relocate or anticipates being unavailable during the study follow-up period.\n5. Child requires urgent medical or dental care that would preclude participation, as judged by the study dentist (children identified with urgent dental needs during screening will be referred for appropriate care and their eligibility will be determined by the study protocol).\n6. More than one eligible child from the same household is enrolled; in such cases, one child will be selected according to the study protocol to maintain independence of observations.",{"count":236,"type":22},1200,[119],"This study will evaluate the effectiveness and implementation of a theory-driven, WhatsApp-based family engagement intervention designed to improve oral health among primary school children. Parents or primary caregivers will be randomly assigned (individually or by school, depending on the study design) to either receive the digital intervention or usual care. The intervention will deliver structured oral health education, behaviour-change messages, reminder prompts, short videos, interactive quizzes, and parent-child brushing activities through WhatsApp over a predefined intervention period (e.g., 6-12 months).\n\nThe primary effectiveness outcomes will include improvements in children's oral hygiene status (e.g., OHI-S, Plaque Index, Gingival Index, and dental caries where appropriate) and oral health behaviours such as twice-daily toothbrushing and reduced sugary snack consumption. Secondary outcomes may include parental oral health literacy, self-efficacy, and supervised brushing practices.\n\nAlongside effectiveness, the study will assess implementation outcomes-including acceptability, feasibility, adoption, fidelity, reach, and sustainability-to determine whether the intervention can be successfully integrated into routine school and community oral health programmes. Findings will provide evidence on both whether the intervention works and how it can be implemented and scaled in low- and middle-income countries.",[30,240,241],"Family Engagement","Oral Health Behavior Change",[30,243,240,244],"Parents","Children's oral health, family engagement, parents, caregiver engagement, WhatsApp, digital health, mHealth, oral health promotion, oral hygiene,","2026-07-25",{"date":247,"type":35},"2026-07-30",{"date":249,"type":22},"2026-08-01",{"date":251,"type":22},"2027-05-31",{"name":253,"class":107},"Universiti Putra Malaysia",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":51,"sex":18,"minAge":81,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":271,"leadSponsor":273,"locationsCount":4},"100649289","effects-of-topical-anesthetics-on-pain-and-anxiety-in-children-100649289","NCT07733622","Effects of Topical Anesthetics on Pain and Anxiety in Children","Evaluation of the Effects of Different Topical Anesthetic Agents on Pain and Anxiety in Pediatric Patients","Inclusion Criteria:\n\n* Children aged 6 to 8 years.\n* Frankl Behavior Rating Scale score of 3 or 4.\n* No previous history of local anesthetic injection for dental treatment.\n* Requiring maxillary infiltration anesthesia for treatment of a maxillary second primary molar.\n* Requiring non-emergency, painless dental treatment.\n* Medically healthy children with no chronic systemic disease, mental disability, or physical disability.\n* Written informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Frankl Behavior Rating Scale score of 1 or 2.\n* Physical or intellectual disability.\n* History of cardiovascular disease, diabetes mellitus, Graves' disease, epilepsy, hyperthyroidism, active infection, phenylketonuria, cardiovascular shock, otorrhea, or otitis.\n* Known hypersensitivity or allergy to benzocaine, lidocaine, or any component of the topical anesthetic formulations.\n* Emergency dental treatment or presence of dental pain requiring urgent intervention.\n* Chronic liver or kidney disease.\n* History of methemoglobinemia.","8 Years",{"count":263,"type":22},160,"Dental anxiety and pain associated with local anesthetic injections are among the most common barriers to successful dental treatment in children. Topical anesthetic agents are widely used to reduce discomfort during needle insertion; however, evidence regarding the comparative effectiveness of different formulations remains limited.\n\nThis prospective observational study aims to evaluate the effects of four routinely used topical anesthetic applications (benzocaine spray, benzocaine gel, lidocaine spray, and lidocaine gel) on pain and anxiety during local infiltration anesthesia in pediatric dental patients. The study will include 160 healthy children aged 6-8 years who require maxillary infiltration anesthesia for routine dental treatment. The choice of topical anesthetic will be determined by the treating clinician as part of routine clinical practice, and no additional intervention or treatment modification will be performed for research purposes.\n\nDental anxiety will be assessed using the Modified Child Dental Anxiety Scale-faces version (MCDASf), behavioral responses during local anesthetic administration will be evaluated using the Sound, Eye, and Motor (SEM) scale, and self-reported pain will be measured using the Wong-Baker FACES Pain Rating Scale. Physiological parameters, including heart rate, blood pressure, peripheral oxygen saturation (SpO₂), and body temperature, will be recorded before, during, and after local anesthetic administration. The findings are expected to provide evidence regarding the effectiveness of commonly used topical anesthetic formulations in reducing pain and anxiety during pediatric dental treatment and may contribute to optimizing behavior management strategies in clinical practice.",[266,30],"Dental Anxiety","2026-07-24",{"date":269,"type":35},"2026-07-29",{"date":247,"type":22},{"date":272,"type":22},"2026-09-10",{"name":274,"class":107},"Recep Tayyip Erdogan University Training and Research Hospital",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":51,"sex":18,"minAge":283,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":295,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":73},"100614735","assessment-of-language-comprehension-and-learning-in-children-attending-child-psychiatry-services-ticoala-soins-100614735","NCT07283458","Assessment of Language Comprehension and Learning in Children Attending Child Psychiatry Services (TICOALA-SOINS)","TICOALA-SOINS : Assessment of Language Comprehension and Learning in Children Attending Child Psychiatry Services. Pilot Study of Acceptability and Feasibility.","TICOALA-SOINS","Inclusion Criteria:\n\n* Children (boys or girls) aged 3-7 years\n* Consulting in the child psychiatry service\n* Enrolled in a French-speaking school\n\nExclusion Criteria:\n\n* Inability to use the tablet-based TICOALA tool due to severe sensory (blindness, deafness), motor, or intellectual impairment\n* Refusal of the child or parents\u002Flegal guardians to participate\n* Child not affiliated with the French social security system","3 Years","7 Years",{"count":286,"type":22},50,[119],"Language is central to children's cognitive, emotional, and social development, and language difficulties are a frequent reason for consultation in child psychiatry, often co-occurring with psychiatric disorders. Yet, systematic language assessment is rarely possible due to the limited availability of speech-language therapists in these services.\n\nThe TICOALA tool (Interactive Test of Language Comprehension and Learning on tablet) offers a quick and engaging way to evaluate lexical and syntactic comprehension and word learning. This study aims to assess its acceptability among children aged 3-7 attending a child psychiatry service in Paris, as well as among clinicians and parents. Secondary goals include testing the feasibility of a larger study, describing children's language skills, and examining how these relate to clinical and background variables.",[290,291,292,30,293,294],"Typical Development","Typically Developing Children Ages 3 to 6","Typical Preschoolers Who Can Not Zipper","Children Behavior Problem","FRENCH STUDY",[296],"language assessment","2026-07-20",{"date":299,"type":35},"2026-07-21",{"date":301,"type":35},"2026-03-19",{"date":303,"type":22},"2028-03-19",{"name":305,"class":107},"Centre Hospitalier St Anne",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":261,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":73},"100647769","the-effect-of-bedside-yoga-intervention-on-early-mobilization-in-children-100647769","NCT07715487","The Effect of Bedside Yoga Intervention on Early Mobilization in Children","The Effect of Bedside Yoga Intervention on Early Mobilization in Children Undergoing Surgery","Inclusion Criteria:\n\n* Hospitalized in a pediatric surgery unit for surgery.\n* Able to participating in pediatric yoga.\n* Able to understand and communicate in Turkish.\n\nExclusion Criteria:\n\n* none",{"count":117,"type":22},[119],"The postoperative period is a critical phase in which early mobilization can accelerate recovery and reduce the risk of complications. Early movement improves lung ventilation, thereby decreasing the likelihood of atelectasis and pneumonia, while also enhancing circulation to prevent deep vein thrombosis and pulmonary embolism. Furthermore, it promotes bowel motility, reduces the risk of constipation and ileus, preserves muscle strength, and improves overall well-being. Early mobilization has also been associated with better pain control, enhanced psychological well-being, reduced complication rates, and shorter hospital stays. However, in pediatric patients, factors such as pain, anxiety, and fear may delay the mobilization process.\n\nYoga has emerged as a promising non-pharmacological intervention due to its combination of breathing exercises, relaxation techniques, and gentle physical movements. Previous studies have demonstrated that yoga can reduce pain perception, improve pain tolerance, alleviate stress-related symptoms, and support physical recovery in children. Evidence suggests that yoga-based interventions may contribute to pain management by promoting relaxation and reducing psychological distress. In postoperative settings, bed-based yoga exercises have been reported to facilitate musculoskeletal relaxation, improve respiratory function, decrease anxiety and stress levels, and encourage earlier mobilization. Systematic reviews have further indicated that yoga may enhance both physical and psychological recovery following surgery, particularly through its effects on pain reduction and functional rehabilitation.\n\nAlthough the benefits of bed-based yoga have been documented in adult surgical populations, research focusing on pediatric surgical patients remains limited. Therefore, this study aims to evaluate the effect of bed-based yoga on early mobilization in pediatric surgical patients during the postoperative period. By investigating the effectiveness of this non-pharmacological intervention, the study seeks to address an important gap in the literature and contribute to evidence-based postoperative nursing care practices.",[30,317],"Yoga Therapy",[319],"Yoga therapy, pediatric surgery","2026-07-17",{"date":297,"type":35},{"date":323,"type":22},"2026-07-01",{"date":325,"type":22},"2026-10-30",{"name":327,"class":107},"Cukurova University",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":18,"minAge":261,"maxAge":82,"enrollmentInfo":335,"targetDuration":4,"studyType":23,"phases":337,"briefSummary":338,"conditions":339,"keywords":345,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":73},"100644489","think-find-solve-activities-for-insulin-self-management-in-type-1-diabetes-100644489","NCT07670572","Think-Find-Solve Activities for Insulin Self-Management in Type 1 Diabetes","The Effect of Think-Find-Solve Activities on Insulin Self-Management in Children With Type 1 Diabetes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* For the child:\n\nDiagnosed with Type 1 diabetes Aged between 8 and 12 years Able to read and write Able to understand and speak Turkish Diagnosed with diabetes for at least one year Regularly attending routine three-month outpatient clinic follow-ups Having no other diseases or medical conditions aside from diabetes The child agrees to participate in the study\n\n-For the Parent: Being the mother or father of the child with Type 1 diabetes Being the primary caregiver responsible for the child Able to read and write Agrees to participate in the study\n\nExclusion Criteria:\n\nThe child uses an insulin pump\n\n\\-",{"count":336,"type":22},40,[119],"Children with type 1 diabetes require lifelong insulin therapy. However, improper management of insulin therapy may lead to serious, potentially life-threatening complications. The aim of this study is to examine the effect of an activity book developed for insulin therapy on insulin self-management among children with type 1 diabetes and their parents. The study is designed as a cluster randomized controlled experimental trial at the center level, including pre-test, 1- month, and 3-month follow-up measurements. The study will be initiated after obtaining ethical approval and institutional permissions. The sample will consist of children aged 8-12 years with type 1 diabetes and their parents. The study will be conducted in two different hospitals in Istanbul; using cluster randomization, one hospital will be assigned to the intervention group and the other to the control group. Prior to the main study, a pilot study will be conducted with 15 participants in each group, and the sample size will be calculated using G\\*Power based on the pilot data. Data will be collected using the \"Descriptive Information Form for Children with Diabetes\" and the \"Insulin Treatment Self-Management Scale (ITSMS) - Child (8-18 years) and Parent Forms.\" The \"Find-Solve-Learn Insulin Self-Management Activity Book\" will be applied to the children in the intervention group. The children will be monitored to complete the activity book at least twice a month for three months, and feedback will be obtained from their families regarding the process. The data collection process will include pre-test, 1-month, and 3-month follow-up measurements. The obtained data will be analyzed using appropriate statistical methods.",[340,30,341,342,343,344],"Type 1 Diabetes","Activity","Insulin","Self Management","Parent",[346,347,348,349,350,351],"type 1 diabetes","children","activity","insulin","self management","parent",{"date":297,"type":35},{"date":354,"type":22},"2026-07-15",{"date":356,"type":22},"2027-06-15",{"name":358,"class":107},"Marmara University",{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":51,"sex":18,"minAge":365,"maxAge":82,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":369,"conditions":370,"keywords":374,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":384,"leadSponsor":386,"locationsCount":388},"100647147","treatment-of-mandibular-overjet-in-children-with-maxillary-retrognathism-100647147","NCT07706400","Treatment of Mandibular Overjet in Children With Maxillary Retrognathism","Inclusion Criteria:\n\n* Mandibular overjet due to maxillary retrognathia (Overjet \\\u003C\u002F= 0 mm)\n* Age 9-12 years\n* Informed consent from parents\u002Fguardians\n\nExclusion Criteria:\n\n* Mandibular overjet mainly due to mandibular prognathism\n* Known general and\u002For craniofacial syndromes\u002Fdiseases\n* Adenoid vegetations, hypertrophic tonsils and significantly reduced air passage through nose (mouth breathing), which must be primarily treated\n* Functional disorders in muscles and jaw joints, which must be primarily treated","9 Years",{"count":367,"type":22},180,[119],"The project involves a 10-year prospective longitudinal cohort multicentre study where orthodontic treatment and treatment effect is followed in children with Cl III due to maxillary retrognathia who undergo standardized orthodontic interceptive treatment. Standard clinical procedures are followed as usual at each clinic where standard diagnostic and follow up materials are taken before treatment, after treatment and follow ups after 5 and 10 years. The project will not introduce or test new treatment modalities, additional procedures or behavioural regulation in relation to normal clinical practice or new medical devices. The standard diagnostic and follow up materials in each clinic include examination of the dentition, occlusion, craniofacial morphology, and orofacial function. The analyses are based on the following standardized registration methods which are carried out on all the patients. Information from the patient record is included.\n\nThe patient related outcome measurements will be assessed by five different questionnaires. No biological material is collected for the project.",[371,30,372,373],"Maxillary Retrognathism","Treatment","Class III Malocclusion",[375,376,377,347,378,379,380],"Class III malocclusion","maxillary retrognathism","mixed dentition","permanent dentition","maxillofacial surgery","Face mask","2026-07-13",{"date":354,"type":35},{"date":220,"type":22},{"date":385,"type":22},"2038-07-31",{"name":387,"class":107},"Malmö University",3,{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":396,"maxAge":284,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":399,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":411,"locationsCount":73},"100641205","phase-2-oral-versus-intravenous-magnesium-on-emergence-delirium-100641205","NCT07655817","Oral Versus Intravenous Magnesium on Emergence Delirium","Effect of Oral Versus Intravenous Magnesium on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Two-Center, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Children aged 4 to 7 years\n* American Society of Anesthesiologist (ASA) Status I or II\n* Planned for an adenotonsillectomy procedure under sevoflurane general anesthesia.\n\nExclusion Criteria:\n\n* Parents declined to participate in the trial\n* Behavioral changes, neurological or psychiatric problems\n* Anticonvulsant or sedative drugs\n* Physical or developmental abnormalities\n* Allergies to magnesium\n* cardiovascular, renal, bone, or gastrointestinal diseases.","4 Years",{"count":398,"type":22},360,[400,25],"PHASE2","This prospective randomized controlled study will be conducted to compare the effects of preoperative oral magnesium and intraoperative IV magnesium on the incidence and severity of emergence delirium in children undergoing adenotonsillectomy using sevoflurane anesthesia.",[403,404,30,405],"Magnesium","Emergence Delirium","Adenotonsillectomy",{"date":407,"type":35},"2026-07-06",{"date":323,"type":35},{"date":410,"type":22},"2026-12-25",{"name":412,"class":107},"Tanta University",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":430,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":73},"100582242","acupuncture-for-adhd-acupoint-data-mining-clinical-effectiveness-and-interviews-to-explore-treatment-outcomes-100582242","NCT06860763","Acupuncture for ADHD: Acupoint Data Mining, Clinical Effectiveness, and Interviews to Explore Treatment Outcomes.","Clinical Study on Acupuncture Treatment for Attention Deficit Hyperactivity Disorder.","ACU-ADHD","Inclusion Criteria:\n\nPatients will be considered for enrolment if they meet the criteria of:\n\n* A confirmed diagnosis of ADHD based on the DSM-5 criteria for ADHD (Western medical diagnosis) and in accordance with the ADHD Chinese Medicine Clinical Trial Design and Evaluation Technical Guidelines.\n* Aged between 6 and 12 years.\n* No use of any other pharmacological treatments (both Western and traditional Chinese medicine) within the two weeks prior to the start of the study.\n* An IQ score of greater than 80, as determined by the Raven's Progressive Matrices test.\n* The participant has not participated in any other clinical trials.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if they meet any of the following criteria:\n\n* Do not meet the inclusion criteria\n* Have comorbid psychiatric disorders, severe medical or psychiatric conditions that may interfere with the study (e.g., epilepsy, severe anxiety), pervasive developmental disorders, intellectual disability, or a history of suicidal or self-harming behavior\n* Have participated in any other drug clinical trials within the past 3 months.\n* Have severe comorbid conditions such as cardiovascular, hepatic, renal, or hematologic diseases.\n* Have any other conditions that the researchers believe may interfere with the assessment of treatment efficacy or safety.",{"count":84,"type":22},[119],"This study aims to evaluate the efficacy of acupuncture as a treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-12 years. Using a mixed-methods approach, the research will triangulate data from acupoint data mining, treatment outcomes assessment, and patient perspectives to provide a comprehensive analysis of acupuncture's potential therapeutic benefits for ADHD.\n\nThis prospective cohort study will recruit children diagnosed with ADHD, assigning them to receive either acupuncture combined with traditional Chinese herbal treatment or herbal treatment alone. Quantitative assessments using the the SNAP-IV, Conners 3-P, BRIEF-2, PedsQL™ 4.0 Generic Core Scales, PSQI and CGI that will be complemented by qualitative interviews to capture nuanced patient experiences and treatment outcomes.\n\nThe study will span 12 months, commencing on March 1st, 2025 with an expected completion by February 28th, 2026. By integrating quantitative assessments with qualitative insights, it aims to provide comprehensive evidence on acupuncture's role in ADHD management. Findings may inform clinical guidelines and enhance patient-centered care approaches.",[425,426,30,427,428,429],"Acupuncture","ADHD - Attention Deficit Disorder With Hyperactivity","Interview","Executive Functioning","Quality of Life (QOL)",[425,431,432,427,433,434],"ADHD","Executive functioning","TCM","PedsQL","2026-06-21",{"date":437,"type":35},"2026-06-23",{"date":439,"type":35},"2024-10-15",{"date":441,"type":22},"2027-01-31",{"name":443,"class":107},"The Third Affiliated Hospital of Beijing University of Chinese Medicine",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":51,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":459,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":73},"100415769","effect-of-nano-structured-alumina-coating-on-the-bond-strength-of-zirconia-resin-bonded-fixed-dental-prostheses-100415769","NCT04693949","Effect of Nano-structured Alumina Coating on the Bond Strength of Zirconia Resin-bonded Fixed Dental Prostheses","Inclusion Criteria:\n\n1\\. Patients with missing central or lateral incisor\n\nExclusion Criteria:\n\n1. inadequate edentulous space for the pontic\n2. signs of bruxism\n3. abutment tooth with active periodontal or periapical disease\n4. inadequate enamel bonding surface of the abutment tooth\n5. inadequate interocclusal space for a retainer wing and a proximal connector\n6. pontic guidance\n7. physical or psychological disease likely to interfere with normal conduct of the study",{"count":451,"type":22},80,[119],"The purpose of this study is to evaluate the clinical outcome of resin-bonded fixed dental prostheses (RBFDPs) pretreated with nanostructured alumina coating (NAC).\n\nThe study adopts a prospective, randomized, controlled, double-blind design contrasting the use of NAC to air-borne particle abrasion (APA) (control) as a surface pretreatment method of zirconia RBFDPs used for replacing missing central or lateral incisors. The primary outcome evaluated is the retention\u002Fsurvival of the zirconia RBFDPs pretreated with APA and NAC.",[455,456,30,457,458],"Missing Incisors","Zirconia Surface Pretreatment","Adults","Debonding",[460,461,462],"Airborne particle abrasion","Nanostructured alumina coating","Resin-bonded fixed dental prostheses","2026-06-18",{"date":437,"type":35},{"date":466,"type":35},"2018-01-03",{"date":468,"type":22},"2030-01-01",{"name":470,"class":107},"University of Ljubljana, Faculty of Medicine",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":176,"maxAge":478,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":73},"100642620","active-airways-for-children-and-young-people-with-asthma-100642620","NCT07643753","Active Airways for Children and Young People With Asthma","The Feasibility of an Exercise and Asthma Educational Programme 'Active Airways' on Health Outcomes in Children and Young People With Asthma With All Severities","Inclusion Criteria:\n\nWilling and able to consent to participate in the trial\n\nAble to understand written and spoken English\n\nA diagnosis of Mild to Moderate Asthma or Severe Asthma based on the European Respiratory Society (ERS)\u002F American Thoracic Society (ATS) consensus statement on Severe Asthma\n\nAble to participate in a formal exercise programme\n\nAged 10-17 years\n\nAble to engage in focus groups\n\nApproximately 130cm tall (to be able to complete cardiopulmonary exercise testing (CPET))\n\nExclusion Criteria:\n\nSelf-reported uncontrolled severe exercise-induced breathlessness\n\nRequired a course of antibiotics or oral corticosteroids within the 4 weeks prior to the study commencing\n\nChildren with severe co-morbidities that will not allow them to participate in an exercise programme e.g. Severe neuromuscular disorders, recent fractures or surgeries, cognitive or behavioural conditions.\n\nParticipant is unable or unwilling, in the opinion of the investigator, to give informed consent","17 Years",{"count":117,"type":22},[119],"What is this study about? The investigators want to see if exercise and education sessions can help children and young people (aged 10-17) with asthma, manage the participants asthma better.\n\nThe investigators will place participants that are recruited to this study into one of three groups by a computer (randomly):\n\nGroup 1:\n\nUsual Care: Continue with normal asthma treatment.\n\nGroup 2:\n\nEducation: Usual care + a 45-minute online asthma education class once a week.\n\nGroup 3:\n\nExercise \\& Education: Usual care + 3 exercise sessions a week and asthma education classes.",[483,484,30],"Asthma Childhood","Exercise",[486,347,487,488],"asthma","exercise","physical activity","2026-06-09",{"date":491,"type":35},"2026-06-11",{"date":493,"type":22},"2026-07",{"date":495,"type":22},"2030-09",{"name":497,"class":107},"University of Leicester",{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":18,"minAge":284,"maxAge":82,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":73},"100643583","effects-of-cartoons-and-mobile-games-on-preoperative-anxiety-and-fear-in-children-with-appendicitis-an-rct-100643583","NCT07640230","Effects of Cartoons and Mobile Games on Preoperative Anxiety and Fear in Children With Appendicitis: An RCT","Apandisit Tanısı Ile Cerrahi Servise Yatırılan Çocuklarda Preoperatif Kaygı ve Korkunun Azaltılmasında Çizgi Film ve Mobil Oyunların Etkisi: Randomize Kontrollü Bir Araştırma","Inclusion Criteria:\n\n* Being hospitalized in the Pediatric Surgery Service with a diagnosis of appendicitis.\n* Being between the ages of 7 and 12 years.\n* Voluntary consent\u002Fassent from both the child and their parents to participate in the study.\n* Absence of any visual, auditory, or cognitive problems that prevent communication.\n* Not having received any analgesics before the intervention.\n\nExclusion Criteria:\n\n* Refusal to participate in the study voluntarily.\n* Having a condition that prevents communication due to vision, hearing, speech, or mental health status.\n* Being in an agitated state or unable to cooperate.\n* Having received analgesics due to pain before the study.",{"count":506,"type":22},69,[119],"his study aims to evaluate the effects of cartoon viewing and mobile game playing on preoperative anxiety and fear levels in children aged 7-12 years who are hospitalized for appendicitis surgery. The study is designed as a randomized controlled trial with three groups: a cartoon group, a mobile game group, and a control group receiving routine care.\n\nChildren in the intervention groups will watch a cartoon or play a mobile game for 10 minutes before surgery. Anxiety and fear levels will be measured using validated scales before and after the intervention. The findings of this study are expected to contribute to atraumatic care practices by providing simple and effective non-pharmacological methods to reduce preoperative anxiety and fear in children.",[510,30,511,189],"Preoperative Anxiety","Appendicitis (Diagnosis)","2026-06-08",{"date":514,"type":35},"2026-06-10",{"date":516,"type":35},"2025-10-10",{"date":518,"type":22},"2026-05-30",{"name":520,"class":107},"Ankara City Hospital Bilkent",{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":73},"100596318","phase-2-romiplostim-n01-for-chemotherapy-induced-thrombocytopenia-in-pediatric-cancer-patients-100596318","NCT07043894","Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients","A Prospective, Multicenter Study on the Efficacy and Safety of Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia (CIT) in Children, Adolescents, and Young Adults (CAYA) With Hematological and Solid Tumors","Inclusion Criteria:\n\n1. Voluntary participation with signed informed consent.\n2. Aged 6-24 years, any gender.\n3. ECOG performance status 0-2.\n4. Histologically\u002Fcytologically confirmed non-myeloid malignancy requiring high-intensity chemotherapy with ≥1 myelosuppressive agent.\n5. Patients with potential curative opportunity eligible for standard therapy.\n6. Chemotherapy-induced thrombocytopenia (platelets \\\u003C75×10⁹\u002FL).\n7. Anticipated survival ≥8 months.\n8. Planned ≥2 additional chemotherapy cycles (21-\u002F28-day cycles).\n9. Laboratory parameters meeting:\n\n   * Renal function: Cr ≤1.5×ULN; Ccr ≥55 mL\u002Fmin.\n   * Hepatic function:\n\n     * Total bilirubin ≤1.5×ULN; ALT\u002FAST ≤3×ULN;\n     * For liver metastasis\u002Fcholangiocarcinoma: bilirubin ≤3×ULN, transaminases ≤5×ULN.\n10. No participation in other drug trials within 4 weeks.\n11. Good compliance with efficacy\u002Fsafety follow-up per protocol.\n12. Absence of severe complications (e.g., active GI bleeding\u002Fperforation, jaundice, obstruction, non-cancer fever \\>38°C).\n13. Ability to comprehend and sign informed consent.\n\nExclusion Criteria:\n\n1. Hematologic disorders (non-CIT etiology): AML, ITP, MDS, MPN, multiple myeloma, etc.\n2. Non-CIT thrombocytopenia within 6 months (e.g., chronic liver disease, hypersplenism, infection, hemorrhage).\n3. Known hypersensitivity to romiplostim N01 or excipients (cellulose-lactose, L-HPC, magnesium stearate, film coating).\n4. Refractory cytopenias:\n\n   * Hemoglobin \\\u003C50 g\u002FL despite RBC\u002FEPO;\n   * ANC \\\u003C1.0×10⁹\u002FL despite G-CSF.\n5. Pelvic\u002Fspinal\u002Flarge-field radiotherapy within 3 months.\n6. Arterial\u002Fvenous thrombosis within 3 months.\n7. Severe cardiovascular disease (NYHA Class III-IV, arrhythmia with thromboembolic risk, post-CABG\u002Fstent) within 6 months.\n8. Use of rhTPO, rhIL-11, or TPO-RAs (eltrombopag\u002Favatrombopag\u002Fhetrombopag) within 2 weeks.\n9. Investigator-assessed risks compromising safety\u002Fefficacy evaluation.","24 Years",{"count":286,"type":22},[400],"The goal of this clinical trial is to evaluate the efficacy and safety of romiplostim N01 in treating chemotherapy-induced thrombocytopenia (CIT) in children and adolescents\u002Fyoung adults (CAYA; aged 6-24 years) with hematologic malignancies or solid tumors. The main questions it aims to answer are:\n\n* What proportion of participants achieve platelet count recovery (≥100×10⁹\u002FL or an increase of ≥30×10⁹\u002FL from baseline) within 3 weeks of romiplostim N01 treatment?\n* What is the safety profile of romiplostim N01 in this population, including the incidence and severity of adverse events (especially bleeding and thrombosis)? This is a single-arm study (no comparison group). Researchers will assess the outcomes against predefined efficacy thresholds and historical data (e.g., a 60.7% response rate reported for another TPO-RA, hetrombopag).\n\nParticipants will:\n\n* Receive weekly subcutaneous injections of romiplostim N01 (starting dose: 2 µg\u002Fkg).\n* Have their romiplostim dose adjusted weekly based on platelet counts (increase by 1-2 µg\u002Fkg if platelets \\\u003C99×10⁹\u002FL, maximum dose 10 µg\u002Fkg, stop when target recovery is met).\n* Undergo frequent monitoring, including blood tests (especially platelet counts), vital signs, physical exams, and assessment for adverse events and bleeding throughout the treatment and follow-up period.",[533,534,30,535,536],"Solid Tumors","Hematological Tumor","Adolescent","Chemotherapy Induced Thrombocytopenia","2026-05-06",{"date":539,"type":35},"2026-05-07",{"date":541,"type":35},"2025-12-25",{"date":543,"type":22},"2026-09-01",{"name":545,"class":107},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":528,"enrollmentInfo":553,"targetDuration":4,"studyType":23,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":73},"100587312","phase-2-telpegfilgrastim-vs-filgrastim-for-secondary-prevention-of-chemotherapy-induced-neutropenia-in-pediatric-solid-tumors-100587312","NCT06926751","Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors","A Multicenter, Randomized, Controlled Study of Telpegfilgrastim Versus Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Children and Adolescents With Solid Tumors Receiving High-Intensity Chemotherapy Regimens","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed malignant solid tumor requiring high-intensity chemotherapy, with ≥2 remaining chemotherapy cycles, and either:\n\n   * Previous febrile neutropenia(FN) or dose-limiting neutropenia in the prior chemotherapy cycle without prophylactic granulocyte colony-stimulating factor (G-CSF);\n   * Previous FN or dose-limiting neutropenia in the prior chemotherapy cycle despite prophylactic G-CSF.\n2. Age ≥6 to ≤24 years.\n3. Eastern Cooperative Oncology Group Performance Status ≤1.\n4. Normal bone marrow hematopoietic function: hemoglobin ≥75 g\u002FL, white blood cell count ≥3.0×10\\^9\u002FL, platelets ≥80×10\\^9\u002FL, and neutrophils ≥1.5×10\\^9\u002FL.\n5. Anticipated survival ≥8 months.\n6. Willing to participate, with written informed consent signed by the patient or legal guardian.\n\nExclusion Criteria:\n\n1. Bone marrow involvement at screening.\n2. Uncontrolled localized or systemic infection.\n3. Known hypersensitivity to Telpegfilgrastim, recombinant human granulocyte-colony stimulating factor(rhG-CSF), or other pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF) agents.\n4. Concurrent participation in any other investigational drug or device trial.\n5. Severe organ dysfunction: total bilirubin, alanine aminotransferase(ALT), or aspartate transaminase(AST) \\>2.5 × upper limit of normal(ULN) (or \\>5 × ULN in patients with liver metastases), serum creatinine \\>5 × ULN.\n6. Severe psychiatric disorders affecting informed consent provision or adverse event assessment.\n7. Any condition deemed by the investigator to compromise patient safety or interfere with study outcomes, including risks from the investigational product or confounding adverse event evaluation.",{"count":554,"type":22},132,[400],"The goal of this clinical trial is to evaluate the efficacy and safety of Telpegfilgrastim (a PEGylated recombinant human granulocyte colony-stimulating factor, PEG-rhG-CSF) compared to Filgrastim (short-acting rhG-CSF) in preventing chemotherapy-induced neutropenia (CIN) in children and adolescents aged 6-24 years with malignant solid tumors receiving high-intensity chemotherapy regimens. The main questions it aims to answer are:\n\n* Does Tuopefilgrastim reduce the incidence of febrile neutropenia (FN) in the first chemotherapy cycle (Cx+1) compared to Filgrastim?\n* How do the two treatments compare in terms of duration and severity of neutropenia, chemotherapy delays\u002Fdose reductions, antibiotic use, and bone pain incidence? Researchers will compare the Telpegfilgrastim group (3:1 ratio, 99 participants) with the Filgrastim group (33 participants) to determine if Telpegfilgrastim demonstrates superior efficacy and safety.\n\nParticipants will:\n\n* Receive subcutaneous injections of either Telpegfilgrastim (33 μg\u002Fkg, single dose) or Filgrastim (5 μg\u002Fkg\u002Fday, multiple doses) 24 hours after each chemotherapy cycle.\n* Undergo blood tests, physical exams, and temperature monitoring during follow-up visits.\n* Be assessed for bone pain severity using age-appropriate scales (FLACC or Wong-Baker).\n* Complete two chemotherapy cycles with close safety and efficacy monitoring.",[533,30,535,558],"Chemotherapy Induced Neutropenia",{"date":539,"type":35},{"date":561,"type":35},"2025-06-12",{"date":563,"type":22},"2027-09-01",{"name":545,"class":107},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":528,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":73},"100574602","phase-2-a-prospective-single-arm-clinical-study-of-liposomal-mitoxantrone-combination-regimen-in-the-treatment-of-relapsed-and-refractory-solid-tumors-in-children-adolescents-and-young-adults-100574602","NCT06761417","A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults","Main inclusion Criteria:\n\n1. The patient fully understands this study, voluntarily participates and signs the informed consent form (ICF).\n2. Age: children (6 - 12 years old), adolescents (13 - 18 years old) and young adults (19 - 24 years old) (CAYA). The expected survival time is \\> 3 months.\n3. Diagnosed with relapsed and refractory solid tumors by histopathology, and it is one of the following subtypes: (1) bone and soft tissue tumors; (2) neuroblastoma; (3) other types of solid tumors that the investigator deems eligible for enrollment.\n4. There must be measurable tumor lesions by CT, enhanced CT, PET\u002FCT or MRI.\n5. Karnofsky score \\> 50; ECOG score ≤ 2.\n6. Bone marrow function: neutrophil count \\> 1.5 × 10⁹\u002FL, platelet count \\> 75 × 10⁹\u002FL, hemoglobin ≥ 80 g\u002FL.\n7. Liver and kidney function: serum creatinine ≤ 1.5 times the upper limit of normal value; AST and ALT \\\u003C 2.5 times the upper limit of normal value (for patients with liver invasion \\\u003C 5 times the upper limit of normal value); total bilirubin \\\u003C 1.5 times the upper limit of normal value (for patients with liver invasion \\\u003C 3 times the upper limit of normal value).\n8. No history of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, no history of clinically severe pericardial disease, or no electrocardiogram evidence of acute ischemic or active conduction system abnormality within 6 months before recruitment.\n\nMain exclusion Criteria:\n\n1. Patients with known hypersensitivity to any component of the study drugs.\n2. Patients with other malignant tumors that are not under control (except for basal cell carcinoma of the skin, in-situ breast\u002Fcervical cancer, and other malignant tumors that have been effectively controlled without treatment in the past five years).\n3. Pregnant, lactating women and women of childbearing age who are unwilling to take contraceptive measures.\n4. Other situations judged by the investigator as not suitable for participating in this study.",{"count":572,"type":22},49,[400],"The aim of this clinical study is to determine the efficacy and safety of the liposomal mitoxantrone combination regimen in treating relapsed and refractory solid tumors among children, adolescents, and young adults. The key questions it intends to address are:\n\nCan the liposomal mitoxantrone combination regimen improve the objective response rate (ORR) compared to historical data? What are the adverse events associated with this combination regimen? Researchers will administer the liposomal mitoxantrone combination regimen (including capecitabine and anlotinib with specific dosing regimens) to the participants and closely monitor their conditions.\n\nParticipants will:\n\nReceive the treatment regimen for 4 - 6 cycles, with each cycle lasting 21 days Undergo regular checkups and tests during the treatment period and follow-up period as per the protocol.\n\nHave their tumor status, blood parameters, and other relevant indicators measured to evaluate the treatment effect and safety.",[533,30,576],"Adolescents",[578,579,580],"Mitoxantrone liposomes","Solid tumor","Children and adolescents",{"date":539,"type":35},{"date":583,"type":35},"2025-01-24",{"date":585,"type":22},"2028-02-01",{"name":545,"class":107},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":18,"minAge":365,"maxAge":82,"enrollmentInfo":594,"targetDuration":4,"studyType":23,"phases":595,"briefSummary":596,"conditions":597,"keywords":598,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":73},"100632115","comparing-game-based-reward-systems-to-support-childrens-engagement-100632115","NCT07509489","Comparing Game-Based Reward Systems to Support Children's Engagement:","Effect of Gamification-Based Incentive Schemes on Behavioral Adherence in Children","Inclusion Criteria:\n\nChildren aged 9-12 years Regular smartphone use (at least 4 days per week) Has access to a smartphone throughout most of the day Brings a smartphone to school Owns a personal smartphone with a touchscreen Owns a smartphone with Android operating system (version 9 or higher) Has access to mobile internet on their device Is allowed to use a smartphone at school during breaks (e.g., lunch or longer breaks) for questionnaire completion and to wear a smartwatch Native Czech speaker\n\nExclusion Criteria:\n\nDoes not meet one or more of the inclusion criteria Has a sibling already enrolled in the study",{"count":263,"type":22},[119],"This Randomized Control Trial evaluates the impact of different gamification-based incentive schemes (levels, streaks and their combination) on adherence to target behaviors in children. Participants are randomized into four groups with different types of motivational frameworks.",[30],[599,600,601],"incentive","financial","behaviour","2026-05-05",{"date":604,"type":35},"2026-05-08",{"date":606,"type":35},"2026-03-28",{"date":608,"type":22},"2027-12-01",{"name":610,"class":107},"Palacky University",{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":619,"maxAge":20,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":623,"conditions":624,"keywords":634,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":643,"leadSponsor":645,"locationsCount":73},"100630322","phase-1-influence-of-lung-volume-optimization-maneuver-on-cardiac-output-and-lung-compliance-in-ventilated-children-with-congenital-heart-disease-undergoing-surgical-repair-100630322","NCT07486167","Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congenital Heart Disease Undergoing Surgical Repair","Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Mechanics in Children With Congenital Heart Disease","ILOCO-CHD","Inclusion Criteria:\n\n* Inclusion Criteria\n* congenital heart disease\n* surgery with cardiopulmonary bypass\n\nExclusion Criteria:\n\n* single ventricle physiology\n* ECMO\u002FVAD\n* \\\u003C36weeks of gestational age\n* chronic lung disease\n* Endotracheal tube leak \\> 15%\n* lack of informed consent from parents.","0 Days",{"count":451,"type":22},[622,400],"PHASE1","The aim of this randomized interventional multi-center clinical trial is to determine whether a standardized lung volume optimization maneuver (LVOM), including PEEP titration, improves outcomes in children undergoing biventricular repair for congenital heart disease (CHD) with cardiopulmonary bypass.\n\nThe primary hypothesis is that optimizing end-expiratory lung volume through a standardized PEEP titration maneuver improves cardiac performance and lung function.\n\nSecondary objectives are to evaluate whether this strategy reduces duration of mechanical ventilation, improves hemodynamics and ventilation-perfusion matching, and decreases the need for vasopressor support.",[625,626,627,628,629,630,631,30,632,633],"Congenital Heart Disease","Cardiopulmonary Bypass","Mechanical Ventilation","Peep Titration in Lung Protective Ventilation","Positive End-expiratory Pressure (PEEP)","Lung Volume","Lung Mechanics","Hemodynamic Changes","Cardiac Surgery",[635,636,637,638],"cardiopulmonary interactions","end-expiratory lung volume","electrical impedance tomography","PEEP titration","2026-04-26",{"date":641,"type":35},"2026-04-30",{"date":543,"type":22},{"date":644,"type":22},"2028-12-31",{"name":646,"class":107},"Charite University, Berlin, Germany",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":51,"sex":18,"minAge":284,"maxAge":654,"enrollmentInfo":655,"targetDuration":4,"studyType":23,"phases":657,"briefSummary":658,"conditions":659,"keywords":664,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":676,"locationsCount":73},"100635450","effects-of-8-week-crossfit-based-concurrent-training-on-fitness-body-composition-and-psychological-outcomes-in-schoolchildren-100635450","NCT07552844","Effects of 8-Week CrossFit-Based Concurrent Training on Fitness, Body Composition, and Psychological Outcomes in Schoolchildren","Effects of an 8-Week CrossFit-Based Concurrent Training Program on Physical Fitness, Body Composition, and Psychological Outcomes in Schoolchildren: A Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n* Age: 7-11 years.\n* Students enrolled at CEIP Pablo García Baena (Córdoba).\n\nFor the experimental group:\n\n* Availability to attend the Triple XXX Box (Polígono Pedroches, C. los Alfareros, Parcel 119, 14014 Córdoba), where both assessments and training sessions will be conducted.\n* Availability to attend training sessions twice per week for the 8-week intervention period.\n* No participation in extracurricular physical activity prior to the start of the CrossFit program.\n\nFor the control group:\n\nNo participation in extracurricular physical activity. Informed consent signed by parents or legal guardians. No medical, psychological, or behavioral contraindications that would prevent participation in physical activity.\n\nExclusion Criteria:\n\n* Children with musculoskeletal injuries, diseases, or medical, psychological, or behavioral conditions that limit physical activity or interfere with the assessment of outcomes.\n* Inability or anticipated difficulty in regularly attending training sessions.\n* Refusal of parents or legal guardians to provide informed consent.","11 Years",{"count":656,"type":22},30,[119],"This study examines the effects of an 8-week CrossFit-based concurrent training program in boys and girls aged 7 to 11 years, comparing an experimental group (n=15) with a control group (n=15). The aim is to assess changes in strength, cardiorespiratory fitness, body composition, and psychological variables such as anxiety, stress, and self-esteem, using field-based physical tests (CMJ, Course Navette, handgrip strength, etc.) and validated questionnaires. The study follows a randomized controlled trial design with pre- and post-intervention assessments. The experimental group will complete two weekly CrossFit sessions adapted for children, while the control group will maintain their usual routine without structured physical training. The hypothesis states that the intervention will significantly improve both physical performance and psychological well-being in the experimental group compared to the control group.",[30,660,661,662,663],"Crossfit","Psychology, Child","Physical Fitness","Body Composition",[347,665,666,667,668,669,662,670],"stress","anxiety","exercise training","crossfit","self-esteem","body composition","2026-04-25",{"date":641,"type":35},{"date":674,"type":22},"2026-06",{"date":493,"type":22},{"name":677,"class":107},"Maimónides Biomedical Research Institute of Córdoba",{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":683,"acronym":684,"eligibilityCriteria":685,"healthyVolunteers":12,"sex":18,"minAge":686,"maxAge":396,"enrollmentInfo":687,"targetDuration":4,"studyType":23,"phases":688,"briefSummary":689,"conditions":690,"keywords":694,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":73},"100590045","phase-4-optimizing-perioperative-analgesia-to-lower-pain-following-cleft-palate-surgery-100590045","NCT06962306","Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery","Perioperative Methadone Use for Cleft Palate Repair: A Randomized Controlled Trial","OPAL-Cleft","Inclusion Criteria:\n\n* Age 6 months to 4 years of age\n* Primary cleft palate repair\n* Signed informed consent by parent or legal guardian\n\nExclusion Criteria:\n\n* History of chronic kidney or liver disease\n* Planned admission to the Pediatric Intensive Care Unit (PICU)\n* Additional procedures under general anesthesia for which opioids would be prescribed\n* Any patient ineligible for study participation at the discretion of the investigators","6 Months",{"count":117,"type":22},[86],"The purpose of this study is to compare the use of short acting opioids (fentanyl\u002Fhydromorphone) with long acting opioids (methadone) for pain control following cleft palate surgery in infants and young children.",[691,187,692,693,30],"Cleft Palate","Postoperative Care","Perioperative Care",[695,696,697,698],"Cleft palate surgery","Perioperative pain management","Analgesia","Methadone","2026-04-10",{"date":701,"type":35},"2026-04-14",{"date":703,"type":35},"2025-06-04",{"date":705,"type":22},"2027-07-04",{"name":707,"class":107},"Duke University"]